Literature DB >> 16545351

RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents.

Peter M R Orth1, J Christian Hesketh, Carmen K H Mak, Yi Yang, Shunping Lin, Gregory N Beatch, Alan M Ezrin, David Fedida.   

Abstract

OBJECTIVE: RSD1235 is a novel antiarrhythmic drug with atria-selective electrophysiological actions on Na(+) and K(+) currents. The mechanism for its protection of ventricular repolarization was assessed by its action on Purkinje fibers, and by block of late sodium current active during repolarization. Further, RSD1235's ability to reverse the pro-arrhythmic actions of the class III agents dofetilide and clofilium was assessed in isolated Purkinje fibers and an in vivo model of torsades de pointes (TdP).
METHODS: Action potential and early after-depolarization (EAD) recordings were made from in situ and isolated rabbit Purkinje fibers at 37 degrees C using floating sharp microelectrodes; late I(Na) was recorded using a whole-cell patch clamp technique of Nav1.5 expressed in HEK cells at 22 degrees C; In vivo, anesthetized methoxamine-sensitized rabbits were used to test the ability of RSD1235 to suppress clofilium-induced TdP.
RESULTS: RSD1235 (0.5-30 microM) had minor dose-dependent effects on action potential duration (APD) at 50% and 90% repolarization in Purkinje fibers, but pre-treatment significantly attenuated the APD-prolonging effects of dofetilide (300 nM). EADs induced by 300 nM dofetilide were terminated by 30 microM RSD1235 in all experiments (n=7). RSD1235 blocked a late component of Na current (I(Na)), which can produce inward currents contributing to EAD formation. RSD1235 pre-treatment (1 micromol/kg/min) or acute infusions prevented/terminated TdP induced by clofilium in 8 of 9 rabbits, and reduced the duration of TdP episodes from 71 +/- 23 s in control to 17 +/- 7 and 14 +/- 14 s at infusion rates of 0.3 and 1.0 micromol/kg/min, respectively (n = 9, p < 0.001).
CONCLUSION: RSD1235 itself has minor actions on repolarization in Purkinje fibers, but can reverse the AP-prolonging actions of class III agents and terminate arrhythmias in a model of TdP. We suggest that these protective actions of RSD1235 may result, at least in part, from its ability to inhibit late I(Na) during action potential repolarization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545351     DOI: 10.1016/j.cardiores.2006.01.026

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  26 in total

Review 1.  Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.

Authors:  Sean T Duggan; Lesley J Scott
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

Review 2.  Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.

Authors:  Sean T Duggan; Lesley J Scott
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 3.  [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].

Authors:  U Ravens; E Wettwer; U Schotten; R Wessel; D Dobrev
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

4.  Persistent (current) in the face of adversity ... a new class of cardiac anti-ischaemic compounds on the horizon?

Authors:  David A Saint
Journal:  Br J Pharmacol       Date:  2009-01-07       Impact factor: 8.739

5.  Calcium-voltage coupling in the genesis of early and delayed afterdepolarizations in cardiac myocytes.

Authors:  Zhen Song; Christopher Y Ko; Michael Nivala; James N Weiss; Zhilin Qu
Journal:  Biophys J       Date:  2015-04-21       Impact factor: 4.033

Review 6.  Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation.

Authors:  Christopher E Woods; Jeffrey Olgin
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

7.  A model of canine purkinje cell electrophysiology and Ca(2+) cycling: rate dependence, triggered activity, and comparison to ventricular myocytes.

Authors:  Pan Li; Yoram Rudy
Journal:  Circ Res       Date:  2011-05-12       Impact factor: 17.367

8.  Tolterodine reduces veratridine-augmented late INa, reverse-INCX and early afterdepolarizations in isolated rabbit ventricular myocytes.

Authors:  Chao Wang; Lei-Lei Wang; Chi Zhang; Zhen-Zhen Cao; An-Tao Luo; Pei-Hua Zhang; Xin-Rong Fan; Ji-Hua Ma
Journal:  Acta Pharmacol Sin       Date:  2016-08-29       Impact factor: 6.150

Review 9.  Novel approaches for pharmacological management of atrial fibrillation.

Authors:  Joachim R Ehrlich; Stanley Nattel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 10.  The cardiac persistent sodium current: an appealing therapeutic target?

Authors:  D A Saint
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.